6,561 Shares in Tempus AI, Inc. (NASDAQ:TEM) Acquired by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC bought a new position in Tempus AI, Inc. (NASDAQ:TEM) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 6,561 shares of the company’s stock, valued at approximately $221,000.

Other institutional investors also recently bought and sold shares of the company. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the 3rd quarter worth approximately $30,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI during the 4th quarter valued at approximately $34,000. FNY Investment Advisers LLC acquired a new stake in Tempus AI during the 4th quarter valued at approximately $67,000. IFP Advisors Inc acquired a new stake in Tempus AI during the 4th quarter valued at approximately $76,000. Finally, US Bancorp DE acquired a new stake in Tempus AI during the 4th quarter valued at approximately $80,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Andrew Polovin sold 13,135 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $45.98, for a total transaction of $603,947.30. Following the completion of the sale, the executive vice president now owns 154,171 shares of the company’s stock, valued at $7,088,782.58. This represents a 7.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bradley A. Keywell sold 265,000 shares of the company’s stock in a transaction on Friday, January 17th. The stock was sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the sale, the insider now directly owns 15,218,365 shares of the company’s stock, valued at $534,164,611.50. The trade was a 1.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,598,969 shares of company stock valued at $317,194,162.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Bank of America lifted their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Piper Sandler decreased their price objective on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. William Blair restated a “market perform” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Finally, Morgan Stanley boosted their target price on shares of Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.18.

Tempus AI Trading Up 6.9 %

Shares of NASDAQ TEM opened at $51.35 on Friday. The firm has a fifty day moving average of $56.35 and a 200 day moving average of $51.39. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.